Insider · CIK 0002062007
Craig Malzahn
Files at RGNX (REGENXBIO Inc.). First filing -, latest -.
In brief
Craig Malzahn files SEC Form 4 as officer at RGNX (REGENXBIO Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Craig Malzahn has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -234 | $9.32 | $2,181 | 81,960 | 41 d ago |
| Jan 6, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +65,847 | $0.00 | $0 | 82,194 | Jan 8, 2026 |
| Jan 6, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to buy)derivative | +35,402 | $0.00 | $0 | 35,402 | Jan 8, 2026 |
| Jan 2, 2026 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -1,238 | $14.40 | $18k | 16,347 | Jan 6, 2026 |
| Sep 1, 2025 | RGNX REGENXBIO Inc. | FTax withholding Common Stock | -234 | $8.93 | $2,090 | 17,585 | Sep 3, 2025 |
Questions about Craig Malzahn
Answered from the filings on this page, as of the latest one.
Is Craig Malzahn buying or selling?
Craig Malzahn has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Craig Malzahn's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Craig Malzahn has 0.
Where does Craig Malzahn file Form 4?
Craig Malzahn has filed Form 4 at RGNX (REGENXBIO Inc.) as Chief Technology Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.